SCHEMBL21361525

SCHEMBL21361525

C=C1CN(S(=O)(=O)c2ccc(N(C)C)cc2)CCCN(CC2CCCCC2)CCCN(S(=O)(=O)N2CCN(c3ccccc3Cl)CC2)C1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CD4 P01730 5/20 0.44
SORT1 Q99523 1/20 0.44
HSD11B1 P28845 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 4/20 0.37
LMNA P02545 3/20 0.37
GAA P10253 1/20 0.37
OPRK1 P41145 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TSHR P16473 1/20 0.36
DRD2 P14416 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MCOLN3 Q8TDD5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361451 0.90 CD4 (0.46) CD4SORT1ALDH1A1LMNAMEN1
SCHEMBL21361494 0.88 CD4 (0.46) CD4SORT1L3MBTL1ALDH1A1LMNA
SCHEMBL23102206 0.88 CD4 (0.43) CD4SORT1L3MBTL1ALDH1A1LMNA
SCHEMBL21361536 0.88 L3MBTL1 (0.42) CD4SORT1HSD11B1L3MBTL1ALDH1A1
SCHEMBL21361567 0.88 NPSR1 (0.44) HSD11B1L3MBTL1ALDH1A1LMNAOPRK1
SCHEMBL21361526 0.88 LMNA (0.41) CD4SORT1ALDH1A1LMNAOPRK1
Hydrochloric Acid SCHEMBL21359286 0.87 CD4 (0.48) CD4SORT1L3MBTL1ALDH1A1LMNA
SCHEMBL23102048 0.87 LMNA (0.45) CD4SORT1L3MBTL1ALDH1A1LMNA
SCHEMBL21361524 0.86 CD4 (0.44) CD4SORT1L3MBTL1ALDH1A1LMNA
SCHEMBL21361532 0.86 CD4 (0.44) CD4SORT1L3MBTL1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G CD4 3678/4885SORT1 2452/4885HSD11B1 258/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3727/4885SORT1 2562/4885HSD11B1 290/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3471/4885SORT1 2267/4885HSD11B1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.